Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
Fellows in Training Learn & Network at ACR Convergence
PHILADELPHIA—The fellows-in-training (FIT) programs at ACR annual meetings are highly valued educational sessions that also offer a forum for fellows to meet and connect with trainees from other programs. Fellows who were not able to meet in person during the pandemic years, particularly those who were in their second or third year of training, welcomed…
The Effect of Upadacitinib on Bone Erosion in Patients with RA
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Peresolimab Promising for RA
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
Sunny San Diego to Welcome ACR Convergence 2023
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
Glucocorticoid Use May Result in Loss of Bone Mineral Density
Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.
ACR Convergence 2022 Closing Session Discusses Research Highlights
PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…
Top 10 Tricks for the Management of Dry Mouth
PHILADELPHIA—Whether due to Sjögren’s disease or something else, dry mouth is a common chief complaint from patients with rheumatic illnesses. Dry mouth isn’t life-threatening, but it can have a serious impact on quality of life. Sialogogues like cevimeline and pilocarpine may benefit some, but not all, patients, but cholinergic side effects often limit their usefulness….
How to Welcome and Care for Gender-Diverse Patients
PHILADELPHIA—Acknowledging the complexities of medical care for transgender (trans) and nonbinary or gender-diverse patients and emphasizing the urgency of doing it right, two experts offered guideposts to clinicians in an ACR Convergence 2022 session titled Dignity and Respect: How to Welcome and Care for Gender Diverse Patients in Your Practice, with advice on providing clinical…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 41
- Next Page »